FDA grants priority review to Takeda’s BLA for dengue vaccine candidate
TAK-003 has been developed based on a live-attenuated dengue serotype 2 virus that offers the genetic backbone for all four vaccine viruses. It is currently being assessed to
The company developed the highly selective BTK inhibitor orelabrutinib for the treatment of autoimmune diseases and cancers. InnoCare co-founder, chairwoman and CEO Dr Jasmine Cui said: “Orelabrutinib’s NDA
SDX is the company’s proprietary prodrug of d-methylphenidate (d-MPH) and is the sole active pharmaceutical ingredient (API) in its lead clinical candidate KP1077. KP1077 is being developed for
The collaboration will focus on discovering and developing nucleic acid-based immunotherapies for selected oncology targets using Harbour BioMed’s heavy chain only antibody discovery platform (HCAb). HCAb’s technology produces